Intra-Cellular Therapies 주식 (NASDAQ: ITCI)

에 대한 최신 뉴스 Intra-Cellular Therapies (NASDAQ:ITCI) 주식

Intra-Cellular Therapies

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

News

Movers

AMKR

BILI

BRFS

IBRX

IRTC

ITCI

OLLI

RKLB

TALO

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 빌리빌리(NASDAQ:BILI)의 주가는 지난주 &#39;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#39; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 21달러 가격 목표를 발표했다. 

빌리빌리와 올리즈 바겐은 지난주 최대 성과를 보인 10개 중형주 중 일부 (6월 16일-6월 22일)

Earnings

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

OTRK

수요일 오전 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: Benzinga Pro의 데이터에 따르면 월스트리트는 애벗 래버러토리스(NYSE:ABT)가 개장 전에 98억 8천만 달러의 매출과 주당 95센트의 분기 수익을 보고할 것으로 예상하고 있다. 애벗 주식은 시간 외 거래에서 1% 상승한 110.30달러를 기록했다.

애벗 래버러토리스, U.S. 뱅코프 및 수요일에 주목해야 할 3가지 주식

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies Inc

12 analysts have shared their evaluations of Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $102.5, a high estimate of $130.00, and a low estimate of $74.00. This current average has increased by 3.02% from the previous average price target of $99.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1728061459_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Intra-Cellular Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Intra-Cellular Therapies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Intra-Cellular Therapies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>All You Need to Know About Intra-Cellular Therapies</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>Breaking Down Intra-Cellular Therapies's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Intra-Cellular Therapies displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 46.44%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -10.06%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Intra-Cellular Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.86%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Intra-Cellular Therapies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.57%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Intra-Cellular Therapies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)

RBC Capital analyst Brian Abrahams maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Outperform and raises the price target from $106 to $108.

Price Target

RBC Capital Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $108

Cantor Fitzgerald analyst Charles Duncan reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and maintains $130 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target

In the latest quarter, 16 analysts provided ratings for Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $97.06, a high estimate of $130.00, and a low estimate of $74.00. Marking an increase of 3.26%, the current average surpasses the previous average price target of $94.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1725645611_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Intra-Cellular Therapies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
To gain a panoramic view of Intra-Cellular Therapies's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>Unveiling the Story Behind Intra-Cellular Therapies</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>A Deep Dive into Intra-Cellular Therapies's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Intra-Cellular Therapies showcased positive performance, achieving a revenue growth rate of 46.44% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.06%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -1.86%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Intra-Cellular Therapies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.57%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.02, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Intra-Cellular Therapies

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585939c1ee7bf600010fe945/nigel-coe">Wolfe Research analyst Nigel Coe</a> upgraded the rating for Eaton Corporation plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) from Underperform to Peer Perform. Eaton shares fell 1.1% to close at $285.72 on Thursday. <a href="https://www.benzinga.com/quote/ETN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank analyst Nicole Deblase upgraded Hubbell Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) from Hold to Buy and raised the price target from $431 to $441. Hubbell shares fell 1.2% to close at $370.42 on Thursday. See how other analysts view this stock.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ffc5e0662ba1f0001bb0ac5/nick-lai">JP Morgan analyst Nick Lai </a>upgraded the rating for NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from Neutral to Overweight and raises the price target from $5.3 to $8. NIO shares gained 14.4% to close at $4.85 on Thursday. <a href="https://www.benzinga.com/quote/nio/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst Charles Duncan upgraded Intra-Cellular Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Neutral to Overweight and boosted the price target from $68 to $92. Intra-Cellular Therapies shares declined 0.3% to close at $72.42 on Thursday. S<a href="https://www.benzinga.com/quote/itci/analyst-ratings">ee how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/630f381cec9f420001742995/benjamin-budish">Barclays analyst Benjamin Budish</a> upgraded the rating for Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Underweight to Equal-Weight and raised the price target from $18 to $20. Robinhood shares gained 2.9% to close at $19.67 on Thursday. <a href="https://www.benzinga.com/quote/hood/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying HOOD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="521" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-1024x521.png" alt="" class="wp-image-534479" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-1024x521.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12.png 1311w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Upgrades

HOOD

HUBB

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

Piper Sandler analyst Charles Duncan upgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Neutral to Overweight and raises the price target from $68 to $92.

Piper Sandler Upgrades Intra-Cellular Therapies to Overweight, Raises Price Target to $92

JP Morgan analyst Jessica Fye maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and raises the price target from $79 to $81.

JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $81

RBC Capital analyst Brian Abrahams maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Outperform and lowers the price target from $107 to $106.

RBC Capital Maintains Outperform on Intra-Cellular Therapies, Lowers Price Target to $106

Cantor Fitzgerald analyst Charles Duncan maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and raises the price target from $120 to $130.

Cantor Fitzgerald Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $130

UBS analyst Ashwani Verma maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Neutral and lowers the price target from $83 to $79.

UBS Maintains Neutral on Intra-Cellular Therapies, Lowers Price Target to $79

Goldman Sachs analyst Corinne Jenkins maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Neutral and lowers the price target from $77 to $74.

Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Lowers Price Target to $74

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and maintains $100 price target.

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target

9 analysts have shared their evaluations of Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $99.0, a high estimate of $120.00, and a low estimate of $78.00. This current average has increased by 2.41% from the previous average price target of $96.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1723035647_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Intra-Cellular Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Intra-Cellular Therapies's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Intra-Cellular Therapies's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>All You Need to Know About Intra-Cellular Therapies</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>Intra-Cellular Therapies: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Intra-Cellular Therapies's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 52.9%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intra-Cellular Therapies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.56%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Intra-Cellular Therapies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -2.07%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (9 Ratings)

Management

Intra-Cellular Therapies Announced That Sanjeev Narula Will Join The Company On August 12, 2024, And Will Serve As Executive Vice President, Chief Financial Officer

Guidance

Intra-Cellular Therapies Sees 2024 CAPLYTA Net Product Sales $650M-$680M

Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. The company reported quarterly sales of $161.400 million which beat the analyst consensus estimate of $157.880 million by 2.23 percent. This is a 45.68 percent increase over sales of $110.792 million the same period last year.

Earnings Beats

Intra-Cellular Therapies Q2 2024 GAAP EPS $(0.16) Beats $(0.20) Estimate, Sales $161.400M Beat $157.880M Estimate

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li>Goldman Sachs cut the price target for Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) from $180 to $174. Goldman Sachs analyst Susan Maklari downgraded the stock from Buy to Neutral. Lennar shares gained 0.5% to close at $170.94 on Friday. <a href="https://www.benzinga.com/quote/LEN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased the price target for NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) from $120 to $140. Piper Sandler analyst Harsh Kumar maintained an Overweight rating. NVIDIA shares fell 2.6% to close at $117.93 on Friday. <a href="https://www.benzinga.com/quote/ITCI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut the price target for Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) from $38 to $37.5. Wedbush analyst Nick Setyan downgraded the stock from Outperform to Neutral. Chuy&#8217;s shares fell 0.7% to close at $37.08 on Friday. <a href="https://www.benzinga.com/quote/CHUY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities decreased Comerica Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) price target from $55 to $53. Truist Securities analyst Brandon King downgraded the stock from Buy to Hold. Comerica shares fell 10.5% to close at $50.42 on Friday. <a href="https://www.benzinga.com/quote/CMA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities boosted the price target for Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) from $6 to $8. B. Riley Securities analyst Mike Crawford downgraded the stock from Buy to Neutral. Redwire shares fell 0.9% to close at $6.98 on Friday. <a href="https://www.benzinga.com/quote/RDW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) price target from $95 to $115. Stifel analyst Mark Astrachan upgraded the stock from Hold to Buy. International Flavors shares fell 1% to close at $95.67 on Friday. <a href="https://www.benzinga.com/quote/IFF/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) price target from $81 to $92. Baird analyst Jeff Johnson upgraded the stock from Neutral to Outperform. Henry Schein shares fell 0.5% to close at $70.34 on Friday. <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) price target from $75 to $70. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. Alaska Air shares gained 1.8% to close at $37.93 on Friday. <a href="https://www.benzinga.com/quote/ALK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $580 to $500. Deutsche Bank analyst Lauren Silberman maintained a Buy rating. Domino&#8217;s shares fell 1.2% to close at $404.17 on Friday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan increased Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) price target from $167 to $194. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Abercrombie &amp; Fitch shares gained 1% to close at $158.51 on Friday. <a href="https://www.benzinga.com/quote/ANF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39876945/s-p-500-logs-worst-weekly-decline-since-april-investor-optimism-falls-further">S&amp;P 500 Logs Worst Weekly Decline Since April; Investor Optimism Falls Further</a></li>
</ul>

CHUY

HSIC

NVDA

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $99.18, a high estimate of $120.00, and a low estimate of $78.00. This current average has increased by 1.96% from the previous average price target of $97.27. 
<img src="https://www.benzinga.com/files/images/story/2024/1721653252_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Intra-Cellular Therapies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Intra-Cellular Therapies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Intra-Cellular Therapies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intra-Cellular Therapies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>Get to Know Intra-Cellular Therapies Better</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>Intra-Cellular Therapies: Financial Performance Dissected</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Intra-Cellular Therapies displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 52.9%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intra-Cellular Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.56%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Intra-Cellular Therapies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.07%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.03, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies

Marc Goodman, an analyst from Leerink Partners, reiterated the Buy rating on Intra-Cellular Therapies (ITCI – Research Report). The associated pric...

Buy Rating Affirmed for Intra-Cellular Therapies Amid Strong Sales and Expansion Potential

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on EyePoint Pharmaceuticals (EYPT – Research Report), S...

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)

Executive reshuffles: Uranium Energy, Nutrien and Logitech International Companies in focus

Invesco Main Street Mid Cap Fund Q2 2024 Review

Analyst Sumant Kulkarni of Canaccord Genuity maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), retaining the price targ...

Intra-Cellular Therapies: A Buy Rating on Strong Commercial Performance and Robust Pipeline

Baird Q2 2024 Small/Mid Cap Growth Equity Fund Commentary

Peaking Back In On Intra-Cellular Therapies

Piper Sandler ups Intra-Cellular to overweight, cites Caplyta potential

Stock moves reflect downgrade for US economic growth outlook - Goldman

Jefferies analyst Andrew Tsai maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report) today and set a price target of $105.00....

Jefferies Keeps Their Buy Rating on Intra-Cellular Therapies (ITCI)

ABBV

ADSK

APPF

ASGN

BEPC

BIIB

BILL

CACI

CAVA

CNMD

CWST

DASH

DAVA

DECK

DOCU

EYPT

FBIN

FTNT

GKOS

GLBE

INSP

IONS

IPGP

JAZZ

LBRDK

LECO

LGIH

LOGI

MANH

MCHP

MNST

MPWR

MRVL

MSTR

NBIX

ORCL

PCTY

PINS

PLTR

PODD

POOL

PRCT

RGEN

ROKU

RXST

SMCI

SPSC

SPXU

SRPT

STEM

TREX

TRGP

TRMB

UPRO

VERX

VLTO

XPEL

ZBRA

Health Care

Press Releases

General

Intra-Cellular Therapies Highlights Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting

Intra-Cellular Therapies to Present at the Jefferies Global Healthcare Conference

Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference

Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Viatris

Zoetis

RBC Capital

Cantor Fitzgerald

Piper Sandler

JP Morgan

이들 중형주들은 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
<ol>
<li>빌리빌리(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>)의 주가는 지난주 &#8216;산구오: 무딩티엔샤(San Guo: Mou Ding Tian Xia)&#8217; 발표 이후 23.32% 상승했다. 또한 JP모건 애널리스트 다니엘 첸(Daniel Chen)은 중국의 빌리빌리를 중립에서 비중확대로 상향 조정하고 <a href="https://www.benzinga.com//node/39418621" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">21</a>달러 가격 목표를 발표했다.</li>
<li>이뮤니티바이오(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>)의 주가는 안크티바(ANKTIVA)가 여러 주에 걸쳐 <a href="https://www.benzinga.com//node/39417764" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">첫 번째 상용 투여량</a>을 투여한 보험 적용 범위를 발표한 이후 지속적인 강세로 22.36% 상승했다.</li>
<li>사솔(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>)은 회사가 법원에서 회사와 토탈에너지스 SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) 마켓팅에 유리한 판결을 내렸다고 발표한 후 주가는 20.89% 상승했다. 또한 손해배상금으로 38.9억 랜드, <a href="https://www.benzinga.com//node/39412202" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">이자로 약 2,300만 랜드</a>를 받았다.</li>
<li>지난주 올리즈 바겐 아울렛 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>)의 주식은 JP모건이 중립에서 <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">비중확대</a>로 평가를 올린 이후 15.25% 상승했다.</li>
<li>인트라-셀룰러 테라피스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>)는 회사가 루마테페론을 주요 우울 장애 환자를 위한 보조 요법으로 평가하고 <a href="https://www.benzinga.com//node/39382029" target="_blank" rel="noreferrer noopener">1차 및 주요 2차 평가변수를 충족</a>시키는 두 번째 3상 시험의 톱라인 결과를 발표한 후 주가는 13.18% 상승했다.      shares advanced 12.06% on overall strength in chip stocks. Also, B. Riley Securities analyst <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">raised the price forecast</a> on the stock from $45 to $50.</li>
<li>앰코 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>)는 전반적인 칩주 강세로 주가는 12.06% 상승했다. 또한 B. 라일리 증권(B. Riley Securities)의 분석가는 주식 가격 <a href="https://www.benzinga.com/quote/AMKR/analyst-ratings" target="_blank" rel="noopener">예측</a>을 45달러에서 50달러로 높였다.</li>
<li>아이리듬 테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>)는 회사가 이전에 공개한 <a href="https://www.benzinga.com//node/39411935" target="_blank" rel="noreferrer noopener">제조 자동화 계획</a>의 초기 단계를 시작한 후 기업의 이정표에 도달했다고 발표한 후 주가는 11.53% 증가했다.</li>
<li>로켓 랩 USA(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>)는 주가는 <a href="https://www.benzinga.com//node/39429411" target="_blank" rel="noreferrer noopener">일본 기업 신스펙티브(Synspective)</a>와 도쿄에서 10개 제품 출시 계약을 체결한 후 11.32% 상승했다.</li>
<li>브레드 파이낸셜 홀딩스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFH#NYSE">BFH</a>)는 에버코어 ISI 그룹(Evercore ISI Group)이 이 주식을 언더퍼폼(Underperform)에서 인-라인(In-Line)으로 평가를 올리고 목표 주가를 42달러에서 45달러로 <a href="https://www.benzinga.com/quote/BFH/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정한 </a>이후 10.81% 상승했다. 또한 또한 RBC 캐피털은 해당 주식에 대해 섹터 퍼폼(Sector Perform) 등급을 유지하고 목표 주가를 38달러에서 45달러로 높였다.</li>
<li>BRF S.A.(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRFS#NYSE">BRFS</a>)의 주식은 10.69% 상승했다.</li>
</ol>
위키미디어 커먼즈를 통한 사진
기사 읽기: <a href="https://kr.benzinga.com/news/%ea%b2%8c%ec%9e%84%ec%8a%a4%ed%83%91%ea%b3%bc-%ec%9e%90%eb%b9%8c%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10%ea%b0%9c%ec%9d%98/" target="_blank" rel="noopener">게임스탑과 자빌은 지난주 최악의 성과를 보인 10개의 대형주 중 일부 (6월 16일-6월 22일)</a>

Comments

Intra-Cellular Therapies

뉴스

에 대한 최신 뉴스 Intra-Cellular Therapies (NASDAQ:ITCI) 주식

월요일, 6월 24, 2024

수요일, 4월 17, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌